Impact of Human Leukocyte Antigen Loci and Haplotypes on Intestinal Acute Graft-versus-host Disease after Human Leukocyte Antigen-matched Sibling Peripheral Blood Stem Cell Transplantation

Fa-Hong Yan1,2, Mei Wang1, Jian-Feng Yao1, Er-Lie Jiang1, Ming-Zhe Han1

1Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
2Department of Hematology, Weifang People’s Hospital, Weifang, Shandong 261041, China

Abstract

Background: Acute graft-versus-host disease (aGVHD) is a common and severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Some studies have found that the presence of certain specific human leukocyte antigen (HLA) loci could affect the occurrence of aGVHD. Meanwhile, the impact of HLA haplotypes on aGVHD has been rarely studied. This study aimed to investigate the effects of HLA loci and haplotypes on intestinal aGVHD.

Methods:Totally, 345 consecutive patients undergoing first HLA-matched sibling peripheral blood stem cell transplantation (PBSCT) from February 2004 to June 2013 at Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, were enrolled in this study. HLA loci and haplotypes of recipients with frequency over 5% were searched and their effects on intestinal aGVHD were investigated. Other important factors including donor age, recipient age, donor-recipient sex combinations, and conditioning regimens were also evaluated using logistic regression. Pure upper gastrointestinal tract aGVHD without diarrhea was excluded because the histological proof was unavailable. The follow-up end-point was 6 months after HSCT.

Results: The cumulative incidence of intestinal aGVHD was 19.4%, with 18.0% of the patients classified as classic aGVHD and 1.4% as persistent, recurrent, or late aGVHD. Multivariate analysis showed that HLA-A31 locus (odds ratio [OR] 2.893, 95% confidence interval [CI] [1.054, 7.935], \(P = 0.039\)), HLA B40-DR15 (OR 3.133, 95% CI [1.250, 7.857], \(P = 0.015\)), and HLA B46-DR9 haplotypes (OR 2.580, 95% CI [1.070, 6.220], \(P = 0.035\)), female donor for male recipient (OR 2.434, 95% CI [1.319, 4.493], \(P = 0.004\)) were risk factors for intestinal aGVHD.

Conclusion: The presence of certain HLA loci and haplotypes may influence the occurrence of intestinal aGVHD in PBSCT with HLA-identical sibling donors.

Key words: Haplotypes; Human Leukocyte Antigen; Peripheral Blood Stem Cell Transplantation

Introduction

Human leukocyte antigen (HLA) loci including HLA-A, -B, -C, -DR, -DQ, and -DP individually along with HLA haplotypes which are comprised HLA loci as a DNA string on one chromosome have been found to be associated with many diseases with autoimmune disorders, such as ankylosing spondylitis (AS),1-2 type 1 diabetes,3-9 inflammatory bowel disease,10-12 with strong association between HLA-B27 and AS being the typical example. HLA loci have also been reported to have impacts on acute graft-versus-host disease (aGVHD),13-24 which is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the influences of HLA haplotypes on aGVHD have been rarely studied.

Address for correspondence: Dr. Ming-Zhe Han, Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
E-Mail: mzhan@medmail.com.cn

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Received: 19-01-2017 Edited by: Yuan-Yuan Ji
How to cite this article: Yan FH, Wang M, Yao JF, Jiang EL, Han MZ. Impact of Human Leukocyte Antigen Loci and Haplotypes on Intestinal Acute Graft-versus-host Disease after Human Leukocyte Antigen-matched Sibling Peripheral Blood Stem Cell Transplantation. Chin Med J 2017;130:1290-5.
Here, we aimed to further investigate the roles of HLA loci and haplotypes in predicting the susceptibility of patients to develop aGVHD. The factors that influence the risk of aGVHD with different grades or target organs may not be all the same even in the same study population.\[^{13,25,26}\] We chose intestinal aGVHD which is significant in both prevalence and mortality as study object and investigated whether HLA loci and haplotypes played roles in its occurrence. We confined our study in a group of HLA-matched sibling peripheral blood stem cell transplantation (PBSCT) recipients without ex vivo T-cell depletion. In addition, we took into account other essential aGVHD-related factors such as donor age, recipient age, donor-recipient sex combinations, stem cell source, and conditioning regimen. In the study, we followed up all of the patients for 6 months after HSCT ignoring some potential late aGHVD.

**Methods**

**Ethical approval**
The research was approved by the Ethics Committee of the hospital (approval number NI2015012-EC-1) in December 2015 and was performed in accordance with the Declaration of Helsinki.

**Patients**
We retrospectively studied the clinical data of 345 consecutive patients undergoing first allo-PBSCT from HLA-matched sibling donors between February 2004 and June 2013 in Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The patients who died or lost to follow-up without symptoms of intestinal aGVHD within 100 days after HSCT were excluded from the study. The median age of the patients at transplantation was 36 years, ranging from 4 to 55 years. Out of the 345 patients, 207 (60%) were male and 138 (40%) were female. None of the grafts underwent ex vivo T-cell depletion. Patients were followed up for 6 months after HSCT. Clinical characteristics of the patients are summarized in Table 1.

**Human leukocyte antigen typing**
HLA typing was performed using polymerase chain reaction sequence specific primer method for low resolution of HLA-A, -B, and -DR loci.

**Acute graft-versus-host disease definition**
Diagnosis and staging of intestinal aGVHD were performed according to Seattle criteria.\[^{26,27}\] Classification of aGVHD was based on NIH criteria.\[^{23}\] Classic aGVHD is defined to occur within 100 days after transplantation, and persistent, recurrent, or late aGVHD is defined to occur beyond 100 days. Possible gut aGVHD with isolated upper gastrointestinal tract symptoms of nausea, vomiting, and anorexia was not included due to the lack of histological proof.

**Statistical analysis**
HLA loci and haplotypes with frequency over 5% (more than 18 positive cases in 345 patients) were manually searched.

**Table 1: Clinical characteristics of patients undergoing first allo-PBSCT from HLA-matched sibling donors (n = 345)**

| Characteristics                        | Values                       |
|----------------------------------------|------------------------------|
| Age (years), median (range)            | 36 (4–55)                   |
| Sex (male:female), n                   | 207:138                     |
| Sex match (donor → recipient), n (%)   | Male → Male 97 (28.1)       |
|                                         | Male → Female 71 (20.6)     |
|                                         | Female → Male 110 (31.9)    |
|                                         | Female → Female 67 (19.4)   |
| Diseases of patients at transplantation, n (%) | 164 (47.5)       |
| AML                                    | 32 (15.1)                   |
| ALL                                    | 40 (11.6)                   |
| MDS                                    | 38 (11.0)                   |
| AA                                     | 35 (10.1)                   |
| Other                                  | 16 (4.6)                    |
| Conditioning regimen, n (%)            | TBI ± Cy ± other 74 (21.4)  |
|                                        | Bu ± Cy ± other 245 (71.0)  |
|                                        | Other 26 (7.5)              |
| GVHD prophylaxis, n (%)                | CsA + MTX 158 (45.8)       |
|                                        | FK506 + MTX 160 (46.4)      |
|                                        | CsA + MTX + other 17 (5.0)  |
|                                        | FK506 + MTX + other 9 (2.6) |
|                                        | CsA 1 (0.3)                 |

AML: Acute myeloid leukemia; ALL: Acute lymphoid leukemia; CML: Chronic myeloid leukemia; MDS: Myelodysplastic syndrome; AA: Aplastic anemia; Bu: Busulfan; Cy: Cyclophosphamide; CsA: Cyclosporine; MTX: Methotrexate, FK506: Tacrolimus; allo-PBSCT: Allogeneic peripheral blood stem cell transplantation; HLA: Human leukocyte antigen; GVHD: Graft-versus-host disease; TBI: Total body irradiation.

Other important known risk factors for aGVHD such as donor age, recipient age, donor-recipient sex combinations, and conditioning regimen (total body irradiation [TBI] or non-TBI) were also considered. Logistic regression was used to analyze the relationships between these factors and intestinal aGVHD. The factors with a $P < 0.10$ in univariate analysis were further analyzed using stepwise multivariate analysis. The factors with $P < 0.05$ in multivariate analyses were considered as statistically significant. The data were analyzed using SPSS version 18.0 (IBM Corp., Armonk, NY, USA).

**Results**

**Frequency of human leukocyte antigen loci and haplotypes**
In total, 30 HLA loci and 45 HLA haplotypes were detected in all patients, including two-locus haplotypes and three-locus haplotypes with frequency over 5%. HLA loci frequencies demonstrated Hardy–Weinberg equilibrium. HLA-A, -B,
and -DR loci and their frequency are shown in Table 2 in descending order. The frequency of HLA haplotypes (not shown in detail) varied from 18.6% (A2-DR15) to 5.2% (A24-B13).

### Incidence of intestinal acute graft-versus-host disease

Intestinal aGVHD occurred in 67 recipients (19.4%). According to NIH criteria, 62 (18.0%) were classified as classic aGVHD and the rest 5 (1.4%) were classified as persistent, recurrent, or late aGVHD. The median occurrence time of intestinal aGVHD in all the recipients was 39 days after HSCT.

### Relationships between all factors and intestinal acute graft-versus-host disease

Univariate analysis showed that HLA loci A31, B48, DR12, HLA haplotypes A2-DR12, B13-DR15, B40-DR15, B46-DR9, donor age, recipient age, donor-recipient sex combinations might be associated with intestinal aGVHD with \( P < 0.10 \), while conditioning regimen and other HLA loci or haplotypes had no significant associations with intestinal aGVHD (\( P > 0.10 \)). Multivariate analysis confirmed that HLA-A31 locus, HLA-B40-DR15 and HLA-B46-DR9 haplotype, female donor for male recipient were risk factors for intestinal aGVHD. HLA-B13-DR15 haplotype tended to decrease the risk of intestinal aGVHD while donor age tended to increase it [Table 3]. Comparisons of intestinal aGVHD incidence among these significant loci and haplotypes positive or negative patients are shown in Table 4.

### Discussion

There have been a number of studies on the association between HLA loci and aGVHD. The HLA loci such as HLA-A10, A11, A26, B18, B35, B44, B49, B50, B54, B61, Cw3, and Cw4 can increase the risk of aGVHD while HLA-Aw19, B8, Bw35, DR1, DR3, DR11, and DR15 can decrease its risk. HLA-A3 and B7 have been reported to have contrasting effects in different studies. [13,14-24] In our study, we found that HLA-A31 allele was a risk factor for intestinal aGVHD. There have been few researches about the influence of HLA haplotypes on aGVHD; we examined this issue and found that HLA-B40-DR15 and HLA-B46-DR9 haplotypes were risk factors for intestinal aGVHD.

HLA-A31 allele has been reported to induce restricted cytotoxic T-lymphocyte (CTL) effect in several kinds of malignant tumors such as melanoma,[29-31] tumors of epithelial origin such as gastric cancer,[32-37] colon cancer,[36,38] prostate cancer,[39-41] lung cancer, cervical cancer, and breast cancer,[36,41] viral infectious diseases or conditions associated with hepatitis B virus,[42] hepatitis C virus (HCV),[43] Epstein–Barr virus,[44] and HIV,[45] as well as rheumatoid arthritis,[46] Takayasu’s arteritis,[47] Vogt–Koyanagi–Harada syndrome,[48] and carbamazepine-induced adverse drug reactions.[49] In addition, many of A31 restricted or presented antigens and peptides have been identified among these diseases, for example, tyrosinase-related protein in melanoma,[29,31] F4.2 and c98 (61–70) peptides in gastric cancer,[42,34,35,37] SART3 (109–118),[39] PSA (16–24), PAP (155–163), PAP (248–257), PSMA (207–215), and PSMA (431–440) in prostate cancer,[40] seven peptides (RLI 522–530, β-tublin 5154-161, β-tublin 5232-240,

### Table 2: HLA-A, -B, -DR loci and their frequency

| Items                  | Frequency (%) |
|------------------------|--------------|
| HLA-A locus            |              |
| A2                     | 55.1         |
| A11                    | 29.3         |
| A24                    | 28.1         |
| A30                    | 17.4         |
| A33                    | 9.6          |
| A1                     | 9.6          |
| A3                     | 9.6          |
| A31                    | 6.4          |
| A26                    | 5.2          |
| HLA-B locus            |              |
| B15                    | 29.3         |
| B13                    | 24.6         |
| B40                    | 23.8         |
| B46                    | 14.2         |
| B51                    | 12.2         |
| B7                     | 9.9          |
| B35                    | 8.4          |
| B48                    | 8.4          |
| B44                    | 8.1          |
| B54                    | 6.4          |
| B58                    | 6.4          |
| HLA-DR locus           |              |
| DR15                   | 32.8         |
| DR9                    | 26.7         |
| DR7                    | 22.6         |
| DR4                    | 22.0         |
| DR12                   | 20.9         |
| DR8                    | 12.5         |
| DR14                   | 12.2         |
| DR11                   | 11.3         |
| DR13                   | 9.9          |
| DR3                    | 5.8          |

HLA: Human leukocyte antigen.

### Table 3: Multivariate analysis for intestinal aGVHD

| Factors                  | OR  | 95% CI         | \( P \) |
|--------------------------|-----|----------------|--------|
| HLA-B40-DR15             | 3.133 | 1.250–7.857    | 0.015  |
| HLA-A31                  | 2.893 | 1.054–7.935    | 0.039  |
| HLA-B46-DR9              | 2.580 | 1.070–6.220    | 0.035  |
| Female donor for male recipient | 2.434 | 1.319–4.493    | 0.004  |
| HLA-DR12                 | 1.842 | 0.649–5.228    | 0.251  |
| HLA-A2-DR12              | 1.088 | 0.326–3.636    | 0.891  |
| Donor age                | 1.045 | 0.996–1.097    | 0.070  |
| Recipient age            | 1.017 | 0.969–1.066    | 0.499  |
| HLA-B48                  | 0.401 | 0.089–1.817    | 0.236  |
| HLA-B13-DR15             | 0.150 | 0.018–1.252    | 0.080  |

OR: Odds ratio; CI: Confidence interval; aGVHD: Acute graft-versus-host disease; HLA: Human leukocyte antigen.
As to the mechanisms of how the HLA alleles affect aGVHD, two main explanations were proposed. One was that HLA molecules differ in their ability to present relevant antigens or peptides to the incoming donor-derived T cells including CD8+ and CD4+ lymphocytes. The other was that the tumor necrosis factor-α (TNF-α) gene is polymorphic and the association of TNF-α haplotype with different HLA alleles leads to different TNF-α secretion level and induces hypo- or hyper-immune reactivity. Maybe, there are certain other genes such as TAP and LMP whose gene polymorphisms also have weak associations with HLA haplotypes leading to different susceptibility to aGVHD.

Despite previous reports about the impacts of HLA loci on aGVHD, there has been only one research referring to influences of HLA haplotypes on aGVHD. Morishima et al. showed that the haplotype HLA-A*3303-Cw*1403-B*4403-DRB1*1302-DQB1*0604-DPB1*0401 reduced the risk of Grade 2 to 4 aGVHD, whereas HLA-A*2402-Cw*0702-B*0702-DRB1*0101-DQB1*0501-DPB1*0402 tended to increase the risk in allo-HSCT. We found that HLA-B40-DR15 and HLA-B46-DR9 haplotypes were risk factors for intestinal aGVHD. HLA-B46-DR9 haplotype has been found to be associated with Chinese Singaporean myasthenia gravis and autoimmune thyroid disease after BMT in Chinese patients. HLA-B40-DR15 haplotype has never been found to be associated with any diseases. In this study, we first demonstrated that this haplotype could increase the risk for intestinal aGVHD. As combinations of HLA alleles, various HLA haplotypes may display different susceptibility to aGVHD with similar mechanisms as the single locus described above (summarized in).

There are many factors influencing aGVHD, among which HLA parity is most important, followed by donor-recipient relationship and stem cell source. Some other factors, such as donor age, recipient age, donor-recipient sex combinations, stem cell source, conditioning regimen, and T-cell depletion, may also play roles in aGVHD. In this study, we controlled these major factors by confining the analysis to HLA-matched sibling PBSC without ex vivo T-cell depletion and incorporated the crucial factors into analysis. Nevertheless, the study still has some limitations. First, it was performed in a single center with a limited group of patients. Second, we could not detect all of the late aGVHD as we are limited to a relatively short follow-up, which might give rise to a little deviation in spite of its low incidence. Third, the study did not cover all of the gut aGVHD because the patients with isolated upper gastrointestinal aGVHD were excluded due to the lack of endoscopic biopsies. However, since most of the patients of this category usually have relatively good prognosis, they require less predictive assessments just as Grade I aGVHD was likewise usually excluded in other studies.

In conclusion, in this study, we further support the significance of HLA loci and haplotypes in aGVHD and found several valuable factors influencing intestinal aGVHD in our ethnic population. These findings may have some implications in donor selection and aGVHD prophylaxis and therapy. Due to the limited patients in a single center, the importance of these findings merits further investigation in a larger scale of population.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Diaz-Peña R, Castro-Santos P, Aransay AM, Bruges-Armas J, Pimentel-Santos FM, López-Larrea C. Genetic study confirms association of HLA-DPA1(*01:03 subtype with ankylosing spondylitis in HLA-B27-positive populations. Hum Immunol 2013;74:764-7. doi: 10.1016/j.humimm.2013.02.001.
2. Lu MC, Yang KL, Tung CH, Huang KY, Yu HC, Liu SQ, et al. Higher LPS-stimulated TNF-alpha mRNA levels in peripheral blood mononuclear cells from Chinese ankylosing spondylitis patients with -308G/A polymorphism in promoter region of tumor necrosis factor: Association with distinct A33/B58/Cw10 haplotypes. Rheumatol Int 2008;29:189-95. doi: 10.1007/s00296-008-0671-z.
3. Kumar N, Kaur G, Tandon N, Kang A, Mehra NK. Genomic evaluation of HLA-DR3+ haplotypes associated with type 1 diabetes. Ann NY Acad Sci 2013;1283:91-6. doi: 10.1111/nyas.12019.

4. Howson JM, Roy MS, Zeitzels L, Stevens H, Todd JA. HLA class II gene associations in African American type 1 diabetes reveal a protective HLA-DRB1*03 haplotype. Diabet Med 2013;30:710-6. doi: 10.1111/dme.12148.

5. Yamashita H, Awata T, Kawasaki E, Ikegami H, Tanaka S, Maruyama T, et al. Analysis of the HLA and non-HLA susceptibility loci in Japanese type 1 diabetes. Diabetes Metab Res Rev 2011;27:844-8. doi: 10.1002/dmr.1234.

6. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep 2011;11:533-42. doi: 10.1007/s11892-011-0223-x.

7. Noble JA, Valdes AM, Varney MD, Carlson JA, Moonsamy P, Fear AL, et al. HLA class I and genetic susceptibility to type 1 diabetes: Results from the type 1 diabetes genetics consortium. Diabetes 2010;59:2972-9. doi: 10.2337/db09-0699.

8. Valdes AM, Thomson G, Barcellos LF. Genetic variation within the HLA class I region of high-risk HLA haplotypes. Genes Immunol 2011;11:209-18. doi: 10.1038/gene.2009.104.

9. Erlich HA, Valdes AM, McDevitt SL, Simen BB, Blake LA, McGowan KR, et al. Next generation sequencing reveals the association of DRB3*02:02 with type 1 diabetes. Diabetes 2013;62:2618-22. doi: 10.2373/dbid-13-1387.

10. Okada Y, Yamazaki K, Umeno J, Takahashi A, Kumasaka N, Ashikawa K, et al. HLA-Cw*1202-B*5201-DRB1*1502 haplotype increases risk for ulcerative colitis but reduces for Crohn’s disease. Gastroenterology 2011;141:864-71.e1-5. doi: 10.1053/j.gastro.2011.05.048.

11. Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: The role of the HLA complex. World J Gastroenterol 2006;12:3626-35. doi: 10.3748/wjg.v12.i23.3628.

12. Lombardi ML, Pirrozi G, Luongo V, Mercuro O, Pace E, Blanco Del Vecchio G, et al. HLA-B27 and autoimmune disease. Autoimmunity 2004;37:429-38. doi: 10.1080/08916930490285243.

13. Kjær S, Börresen-Dale AL,丸山 T, et al. The MHC influences acute graft versus host disease in patients transplanted with HLA-identical bone marrow. Blood 1994;83:1265-70.

14. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, et al. The association of HLA antigen and GVHD in allogeneic hemopoietic stem cell transplantation with histocompatible sibling donor: A prospective study. Bone Marrow Transplant 1995;15:825-8.

15. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56. doi: 10.1016/j.bbmt.2005.09.004.

16. Wang RF, Robbins PF, Kawakami Y, Kang QX, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181:799-804. doi: 10.1084/jem.181.2.799.

17. Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunol 2000;263:17-27. doi: 10.1073/pnas.992637199.

18. Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol 1999;163:2361-7.

19. Takedatsu H, Shichijo S, Azuma K, Takedatsu H, Sata M, et al. Analysis of the HLA and non-HLA susceptibility loci in Japanese type 1 diabetes patients by transplanted HLA-A31-restricted cytotoxic T lymphocytes. J Immunol 2000;165:416-21. doi: 10.4049/jimmunol.165.1.416.

20. Nowakowska K, Ashikawa K, Svetoch Y, Hirohashi Y, Ichimiya S, Wada Y, et al. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes. J Immunol 2004;172:6253-6. doi: 10.4049/jimmunol.172.11.6253.
HLA-A31+ epithelial cancer patients. Int J Oncol 2004;24:337-47. doi: 10.3892/ijo.24.2.337.

37. Sato N, Nabeta Y, Kondo S, Sahara H, Hirohashi Y, Kashiwagi K, et al. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens. Cancer Chemother Pharmacol 2000;46 Suppl:S86-90. doi: 10.1007/PL00014057.

38. Gohara R, Nakao M, Ogata Y, Isomoto H, Oizumi K, Ishik K. Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer. Jpn J Cancer Res 1997;88:198-204. doi: 10.1111/j.1349-7006.1997.tb00366.x.

39. Mohamed ER, Naito M, Terasaki Y, Niu Y, Gohara S, Komatsu N, et al. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. Int J Oncol 2009;34:529-36. doi: 10.3892/ijo_00000178.

40. Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Ishik K, et al. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 2005;11(19 Pt 1):6933-43. doi: 10.1158/1078-0432.CCR-05-0682.

41. Matsueda S, Takedatsu H, Sasada T, Azuma K, Ishihara Y, Komohara Y, et al. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother 2007;30:274-81. doi: 10.1097/01.jii.000021340.88835.e7.

42. Missale G, Redeker A, Person J, Fowler P, Guilhot S, Schlicht HJ, et al. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 1993;177:751-62. doi: 10.1084/jem.177.3.751.

43. Matsueda S, Yamada A, Takao Y, Tamura M, Komatsu N, Yutani S, et al. A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV 1b-infected patients with HLA-A11, -A31, and -A33. Cancer Immunol Immunother 2007;56:1359-66. doi: 10.1007/s00262-007-0284-5.

44. Yazaki M, Takahashi T, Andho M, Akatsuka Y, Ito T, Miyake Y, et al. A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes. Bone Marrow Transplant 1999;24:129-37. doi: 10.1038/sj.bmt.1701856.

45. Veronese Rodrigues Mde L, de Castro Figueiredo JF, Deghaide NH, Romão E, Vieira de Souza N, Donadi EA. Frequency of HLA class I and II alleles in Brazilian patients with AIDS and cytomegalovirus retinitis. Acta Ophthalmol Scand 2003;81:514-6. doi: 10.1034/j.1600-0420.2003.00098.x.

46. Kapitány A, Zilahi E, Szántó S, Szűcs G, Szabó Z, Végvári A, et al. Association of rheumatoid arthritis with HLA-DR1 and HLA-DR4 in Hungary. Ann N Y Acad Sci 2005;1051:263-70. doi: 10.1196/annals.1361.067.

47. Chareonwongse P, Kangwanshiratada O, Boonnam R, Hoomsindhu U. The association between the HLA antigens and Takayasu’s arteritis in Thai patients. Int J Cardiol 1998;66 Suppl 1:S117-20. doi: 10.1016/S0167-5273(98)00158-2.

48. Kim MH, Seong MC, Kwak NH, Yoo JS, Huh W, Kim TG, et al. Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans. Am J Ophthalmol 2000;129:173-7. doi: 10.1016/S0002-9394(99)00434-1.

49. Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol 2012;39:594-601. doi: 10.1111/j.1346-8138.2011.01457.x.

50. Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol 2012;39:594-601. doi: 10.1111/j.1346-8138.2011.01457.x.